ADX71149 (mGlu2 PAM) for the treatment of epilepsy.
Our partnered drug candidate ADX71149 is a novel orally active mGlu2 PAM. ADX71149 has been extensively profiled in preclinical models of epilepsy showing both standalone activity and in combination with SV2A ligands including levetiracetam. Janssen has patented the combination of mGlu2 PAM with SV2A ligands for the treatment of epilepsy and is currently evaluating the development path forward for ADX71149.
Epilepsy is an indication with significant commercial opportunity. Existing therapies frequently provide ineffective control of symptoms or have side effects that discourage adherence.
We believe that ADX71149 may provide significant benefit to patients.